Bank of America Highlights Five Stocks For Investors
Bank of America has identified five stocks it believes are essential for investment portfolios. Among these, Live Nation stands out as a company poised to deliver solid returns for shareholders. Additional stocks that received a buy rating, as noted by CNBC Pro, include Waystar, Barclays, Medline, and Evercore.
Evercore Investment Bank is currently experiencing positive momentum in capital markets. The institution recently announced favorable sales and earnings in its latest quarterly results, with analyst Ebrahim Poonawalla emphasizing that the stock continues to be a top choice for Bank of America. Poonawalla noted that Evercore’s substantial involvement in mergers and acquisitions (M&A) and increasing revenue from non-M&A advisory work will not only promote earnings per share (EPS) growth but also offer some protection to EPS. He also mentioned that Evercore is well-placed within the IPO landscape, categorizing it among boutique investment banks. The stock has risen by 11% in the last three months.
Regarding Live Nation, Bank of America believes the concert entertainment firm is dedicated to growth. Analyst Peter Henderson pointed out the company’s strong positioning driven by robust demand. He remarked, “As a global leader in live entertainment, we view Live Nation as a multi-year growth narrative supported by strong fundamentals and favorable trends in live entertainment.” The report acknowledged regulatory measures that might be excessive but asserted that the stock’s price remains highly attractive. Live Nation is expected to capture sustained growth in live entertainment demand in the medium to long term, bolstered by positive consumer sentiment and spending trends. The stock has shown a 16% increase over the past month.
Bank of America sees potential in Medline, a company focusing on surgical products. Analyst Andrew Aubin recently gave it a buy rating, believing the firm can achieve lasting high-single-digit growth through market share increases and significant mid-surge demand. Aubin described Medline as an industry leader and highlighted the company’s successful history with mergers and acquisitions, suggesting there’s room for further growth. Having gone public in mid-December, Medline’s stock has appreciated by 13% this past month, and Bank of America played a leading role in its IPO.
Turning to Waystar: the company is seen as well-positioned for steady growth, underpinned by persistent demand for revenue cycle management solutions. There are opportunities for Waystar to strengthen relationships with many of the nation’s top hospitals, thanks to changes in the competitive landscape that may pave the way for further growth.
In summary, while certain risks remain, like potential stock sales that could disrupt Evercore’s capital market momentum, the outlook remains optimistic for these companies. Evercore’s substantial M&A involvement and rising non-M&A advisory income are expected to underpin EPS growth, and management’s focus on expanding in the UK could lead to even more upside.
